Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.

Koblish H, Li YL, Shin N, Hall L, Wang Q, Wang K, Covington M, Marando C, Bowman K, Boer J, Burke K, Wynn R, Margulis A, Reuther GW, Lambert QT, Dostalik Roman V, Zhang K, Feng H, Xue CB, Diamond S, Hollis G, Yeleswaram S, Yao W, Huber R, Vaddi K, Scherle P.

PLoS One. 2018 Jun 21;13(6):e0199108. doi: 10.1371/journal.pone.0199108. eCollection 2018.

2.

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E.

Mol Cancer Ther. 2017 Jun;16(6):1054-1067. doi: 10.1158/1535-7163.MCT-16-0568-T. Epub 2017 Mar 23.

3.

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.

Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.

Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.

4.

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Lambert QT, Pradhan A, Roll JD, Reuther GW.

Biochem J. 2011 Aug 15;438(1):155-64. doi: 10.1042/BJ20110351.

5.

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Gordon GM, Lambert QT, Daniel KG, Reuther GW.

Biochem J. 2010 Dec 1;432(2):255-65. doi: 10.1042/BJ20100774.

6.

Activation of JAK2-V617F by components of heterodimeric cytokine receptors.

Pradhan A, Lambert QT, Griner LN, Reuther GW.

J Biol Chem. 2010 May 28;285(22):16651-63. doi: 10.1074/jbc.M109.071191. Epub 2010 Apr 2.

7.

Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.

Cha JY, Lambert QT, Reuther GW, Der CJ.

Mol Cancer Res. 2008 Mar;6(3):435-45. doi: 10.1158/1541-7786.MCR-07-0187.

8.

Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor.

Pradhan A, Lambert QT, Reuther GW.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18502-7. Epub 2007 Nov 14.

9.

Activation of Ras proteins by Ras guanine nucleotide releasing protein family members.

Lambert QT, Reuther GW.

Methods Enzymol. 2006;407:82-98.

PMID:
16757316
10.

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism.

Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ.

Nat Cell Biol. 2002 Aug;4(8):621-5.

PMID:
12134164
11.

RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia.

Reuther GW, Lambert QT, Rebhun JF, Caligiuri MA, Quilliam LA, Der CJ.

J Biol Chem. 2002 Aug 23;277(34):30508-14. Epub 2002 Mar 5.

12.

Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase.

McFall A, Ulkü A, Lambert QT, Kusa A, Rogers-Graham K, Der CJ.

Mol Cell Biol. 2001 Aug;21(16):5488-99.

13.

Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA.

Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, Sondek J, Caligiuri MA, Der CJ.

J Biol Chem. 2001 Jul 20;276(29):27145-51. Epub 2001 May 23.

14.

Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.

Reuther GW, Lambert QT, Caligiuri MA, Der CJ.

Mol Cell Biol. 2000 Dec;20(23):8655-66.

15.

Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.

Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL, Der CJ.

Mol Cell Biol. 1999 Nov;19(11):7759-70.

17.
18.

Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways.

Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, Der CJ.

Mol Cell Biol. 1997 Mar;17(3):1324-35.

19.

Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling.

Quilliam LA, Lambert QT, Mickelson-Young LA, Westwick JK, Sparks AB, Kay BK, Jenkins NA, Gilbert DJ, Copeland NG, Der CJ.

J Biol Chem. 1996 Nov 15;271(46):28772-6.

20.

Heteroduplex formation: a potential source of genotyping error from PCR products.

Hatcher SL, Lambert QT, Teplitz RL, Carlson JR.

Prenat Diagn. 1993 Mar;13(3):171-7.

PMID:
8506218

Supplemental Content

Loading ...
Support Center